Upon diagnosing acute myeloid leukemia (AML), the initial step involves assessing a patient’s eligibility for intensive chemotherapy. The standard treatment protocol for newly diagnosed AML encompasses intensive chemotherapy to achieve complete remission, followed by post-remission therapy, which may include additional chemotherapy and/or stem cell transplantation. Complete response rates to this approach range from 60% to 85% in adults aged 60 or younger.

While this approach has proven effective, the risk of relapse within three years of diagnosis remains a significant concern. Numerous factors contribute to the likelihood of relapse, including short duration of remission, genetic derangements, prior allogeneic transplantation, advanced age, and concomitant comorbidities. These negative prognostic factors underscore the need for continuous exploration of novel therapeutic agents, as relapse remains a formidable barrier to treatment success.

In a new study, researchers Simonetta I. Gaumond, Rama Abdin, Joel Costoya, Andrew V. Schally (awarded the Nobel Prize in Physiology or Medicine in 1977), and Joaquin J. Jimenez from the University of Miami, Florida Atlantic University and Veterans Affairs Medical Center, Miami, investigated newly emerging therapies targeting drug resistance in AML. On April 8, 2024, their new research paper was published in Oncotarget’s Volume 15, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”

Full blog - https://www.oncotarget.org/2024/05/23/combating-doxorubicin-resistant-acute-myeloid-leukemia/

Paper DOI - https://doi.org/10.18632/oncotarget.28579

Correspondence to - Simonetta I. Gaumond - sxg1204@miami.edu

Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28579

Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/

Keywords - cancer, leukemia, AML, resistance, growth hormone-releasing hormone, MIA-602

About Oncotarget 

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us:

Facebook - https://www.facebook.com/Oncotarget/
X - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/@OncotargetJournal
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh

MEDIA@IMPACTJOURNALS.COM

Oncotarget

Combating Doxorubicin-Resistant Acute Myeloid Leukemia

Skin cancer is the most common form of cancer, and melanomas are the most serious form of this disease. “And we project an increase every year of 20 to 30 percent more cases,” said Merve Hasanov, MD, a James skin cancer and melanoma expert whose research focuses on how melanomas metastasize and spread to the brain. In this episode, Hasanov describes how exposure to ultraviolet light from the sun is the leading cause of all the different types of skin cancer, and that family history is another indicator. “Sun exposure creates a cumulative risk over a lifetime and some people, with a fair complexion, are at higher risk,” she said. Precautions that reduce risk “are decreasing your exposure to the sun, using sun block and reapplying every 50 to 90 minutes and avoiding tanning beds, which use UV rays,” Hasanov said. “Wear a hat or long sleeves, and, even when it’s cloudy or during the winter the UV rays are coming from the sun.” Advances in treatment have led to better outcomes for patients, especially when melanomas are detected in the earlier stages, before they have metastasized and spread to other parts of the body. Because of this, “it’s now recommended that you should, once a year, get a thorough dermatological exam,” Hasanov said, and she also explained the A-B-C-D-E method of detecting skin cancer: asymmetry, border, color, diameter and evolving. Immunotherapy has been a big breakthrough for the treatment of melanomas. “Melanomas have a lot of molecular and genetic changes that can be recognized by the immune system,” she explained. “But cancer cells are smart and can shut down the immune system. But immune checkpoint inhibitors [in immunotherapy drugs] take the brakes off the immune system so the T cells better recognize and kill cancer cells.” Hasanov said that the melanomas in 10 to 12 percent of patients diagnosed in the early stages of their disease will eventually metastasize and travel to the brain. “My research focuses on detecting this earlier when we have better treatment options and survival rates,” she said. Hasanov and her lab have developed a scoring system to determine which early-stage melanoma patients are most likely to develop brain metastasizes. These patients can then be screened on a regular basis. “We’re hoping that this information will lead to better guidelines and trying to spread this information to more physicians and oncologists.”

Episode 172: What You Need to Know About Skin Cancer & Melanoma, with Dr. Merve Hasanov

In this episode, Danna Smith, Dr. Easley, and Bennett Olupo delve into the crucial role of community involvement in protecting and restoring Southern forests. Danna Smith, the founder of The Dogwood Alliance, shares her inspiring journey and the mission to ensure everyone has access to a healthy environment. Her impactful work and the culture of care and determination will leave you feeling empowered to make a positive difference in your community.

Forests for the People and with the People: Danna Smith and the Dogwood Alliance

In this episode, Gwen Trice and Dr. Easley explore their families' extensive history with forestry in the United States. Ms. Trice, in particular, details the work she has done as the founder of the Maxville Project to daylight Black history in Wallowa County, Oregon. She recounts cherished memories of her time pursuing the project, as the community and family members shared stories about her family, loggers of color, and community resilience. Like Dr. Easley and Bennett, you will be drawn into the personal narratives and feel a sense of connection with the experiences shared in this episode.

The Hidden History of Oregon's Forests with Gwendolyn Trice

LSAT expert Laura Damone joins Miriam and Kristi to go over all the nuts and bolts of the LSAT, the most common standardized test utilized in law school admissions.

LSAT Nuts & Bolts

What are the major parts of the LSAT and how should you go about preparing for this test? Your hosts do a dive deep with Laura Damone, who is perhaps the biggest LSAT enthusiast on the planet.

LSAT Deep Dive

Kristi, Miriam, and LSAT expert Laura Damone answer a grab bag of your questions on all things LSAT.

LSAT AMA

Kaitlyn Schiess is an author (The Liturgy of Politics and The Ballot and the Bible) and podcaster (The Holy Post and Curiously, Kaitlyn). She joins us to talk about leadership during an election season and how spiritual formation is at the heart of our political engagement. We talk about everything from how to talk about politics at Thanksgiving dinner to how to preach when politics are involved.

33: Spiritual Formation and Politics with Kaitlyn Schiess

Welcome to the YJBM Science News! Join us as we discuss the recent news in healthcare and science across the Yale community. Today, our hosts Mara and Samantha will share some of the most intriguing topics of the past two weeks.

Papers featured in the episode:
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14126
https://onlinelibrary.wiley.com/doi/10.1002/oby.24111
https://onlinelibrary.wiley.com/doi/10.1002/oby.24107
https://www.science.org/doi/10.1126/scitranslmed.adp1720
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823186

More about YJBM at:
https://medicine.yale.edu/yjbm/

Our Instagram:
https://www.instagram.com/theyjbm/

YJBM Science News Podcast: Episode 21

In a recent study, Yale researchers found that unexpected tones — like the third set of tones here — can cause people to make riskier choices if heard right before making a decision. The findings could have implications for day-to-day decision-making and may help researchers better understand illnesses like schizophrenia and depression.

Researchers find unexpected sounds can lead to riskier decision-making

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.

Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/

Combating Doxorubicin-Resistant Acute Myeloid Leukemia

Oncotarget Podcast

Related tracks